updated 11/10/2010 9:16:30 AM ET 2010-11-10T14:16:30

MOUNTAIN VIEW, Calif., Nov. 10, 2010 (GLOBE NEWSWIRE) -- Conceptus, Inc. (Nasdaq:CPTS), developer of the Essure® procedure, the most effective non-surgical permanent birth control method available, today announced it will begin promoting GYNECARE THERMACHOICE®(1) Uterine Balloon Therapy System in U.S. OB/GYN physician offices.  GYNECARE THERMACHOICE® is a global endometrial ablation product that is used to treat excessive uterine bleeding (menorrhagia). The product is manufactured for and marketed by ETHICON™ Women's Health & Urology, a division of Ethicon, Inc.   

"The opportunity to promote both the Essure procedure and GYNECARE THERMACHOICE® to physician offices will enable us to leverage our large, established sales channel," said Mark Sieczkarek, president and chief executive officer of Conceptus. "Since our sales representatives are already familiar with the synergies between GYNECARE THERMACHOICE® and our Essure procedure, we believe they can hit the ground running and begin contributing to the growth of both products." 

About GYNECARE THERMACHOICE®

The GYNECARE THERMACHOICE® Uterine Balloon Therapy system is an outpatient treatment for heavy menstrual bleeding (menorrhagia) due to benign causes in premenopausal women who have completed childbearing. The treatment uses heat to treat the lining of the uterus during a short, minimally invasive procedure that can be performed with a local anesthetic.

GYNECARE THERMACHOICE® is a registered trademark of Ethicon, Inc. For more complete information on GYNECARE THERMACHOICE® indications, contraindications, warnings and precautions, see the risk information available at www.pelvichealthsolutions.com or a consult with a doctor. 

About the Essure® Procedure

The Essure procedure, FDA approved since 2002, is the first permanent birth control method that can be performed in the comfort of a physician's office in less than 10 minutes (average hysteroscopic time) without hormones, cutting, burning or the risks associated with general anesthesia or tubal ligation. Soft, flexible inserts are placed in a woman's fallopian tubes through the cervix without incisions. Over the next three months, the body forms a natural barrier around the micro-inserts to prevent sperm from reaching the egg. The Essure procedure is 99.95% effective based on one year of follow up with zero pregnancies reported in clinical trials, making it the most effective form of permanent birth control on the market. The procedure is covered by most insurance plans, and when it is performed in a doctor's office the cost to the patient may be as low as a simple co-pay.

Three months after the Essure procedure, a doctor is able to perform an Essure Confirmation Test to confirm that the inserts are properly placed and the fallopian tubes are fully blocked, giving the patient reliance on Essure for permanent birth control. Essure has been proven and trusted by physicians since 2002, with more than 465,000 women worldwide having undergone the Essure procedure.

About Conceptus, Inc.

Conceptus, Inc. is a leader in the design, development and marketing of innovative solutions in women's healthcare. The Company manufactures and markets the Essure permanent birth control procedure. The Essure procedure is available in the United States, Europe, Australia, New Zealand, Canada, Mexico, Central and South America and the Middle East.

The Conceptus, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7961

Please visit www.essure.com for more information on the Essure procedure. Patients may call the Essure Information Center at 1-877-ESSURE-1 with questions or to find a physician in their area.

(1)    Essure® Instructions for Use can be found at: www.essuremd.com . GYNECARE THERMACHOICE® Instructions for Use can be found at www.Ethicon360.com

© 2010 Conceptus, Inc-- All rights reserved.  Conceptus, Essure and Your Family is Complete. Your Choice is Clear are registered trademarks and service marks of Conceptus, Inc. 

CC-2573 9NOV10F

© Copyright 2012, GlobeNewswire, Inc. All Rights Reserved

Discuss:

Discussion comments

,

Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments

Data: Latest rates in the US

Home equity rates View rates in your area
Home equity type Today +/- Chart
$30K HELOC FICO 4.71%
$30K home equity loan FICO 5.26%
$75K home equity loan FICO 4.70%
Credit card rates View more rates
Card type Today +/- Last Week
Low Interest Cards 13.42%
13.42%
Cash Back Cards 17.94%
17.94%
Rewards Cards 17.14%
17.14%
Source: Bankrate.com